Active substance
Results for the substance siltuximab
2 results
About this active substance
Siltuximab is a monoclonal antibody used for the treatment of multicentric Castleman disease (MCD) in patients who are not infected with HIV or HHV-8. It works by binding to interleukin-6 (IL-6), an inflammatory mediator, reducing inflammation and symptoms associated with the disease.
The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to be monitored to prevent adverse reactions and to assess the response to treatment.
Patients should be aware of potential side effects, such as injection site reactions, infections, or elevated lipid levels. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, infections, and elevated lipid levels. In rare cases, severe reactions such as anaphylactic reactions or serious infections may occur. Patients should be informed of these risks before administration.
The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to be monitored to prevent adverse reactions and to assess the response to treatment.
Patients should be aware of potential side effects, such as injection site reactions, infections, or elevated lipid levels. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, infections, and elevated lipid levels. In rare cases, severe reactions such as anaphylactic reactions or serious infections may occur. Patients should be informed of these risks before administration.